Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with or without iodine-125 seed implantation for advanced cervical cancer
ChiCTR1800019571Phase 2Not yet recruiting
- Sponsor
- The First People's Hospital of Yueyang
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in Cervical Cancer (CC) (3 arms), sponsored by The First People's Hospital of Yueyang. Primary endpoints: Objective response rate, Disease control rate and 1 more. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800019571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019571.